Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARMOUR Residential REIT, Inc. (ARR) vs Incyte Corporation (INCY) Price & Performance

ARMOUR Residential REIT, Inc.Trade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

ARMOUR Residential REIT, Inc. vs Incyte Corporation — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.7 (market cap $2.07B), while Incyte Corporation trades at $120.57 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 11.9× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

ARRINCY
Market Cap
$2.07B$24.54B
Sector
FinancialsHealth
52-Week High
$19.12$129.93
52-Week Low
$14.05$81.61
Dividend Yield
17.28%
Enterprise Value
$20.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARMOUR Residential REIT, Inc.

ARMOUR Residential REIT (ARR) trades at $16.54, down 0.84% on the day, amid a bearish technical signal. The stock shows a low P/E of 3.78 and trades below book value (P/B 0.91), suggesting potential undervaluation. Recent earnings were mixed, with a Q2 2026 beat but a Q4 2025 miss. The company maintains a high net income margin of 97.43% and consistent dividend payments, with the latest being $0.24 per share. Cash flow from operations improved to $319 million in 2026, though investing outflows remain high.

ARR presents a value opportunity with strong profitability and dividends, but faces risks from volatile earnings, high investing cash outflows, and a bearish technical outlook. Analyst sentiment is mixed, with 60% hold ratings. The stock's appeal hinges on sustained dividend payments and earnings stability amid interest rate sensitivity.

Incyte Corporation

INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.

Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.

Returns comparison

Trailing returns across standard periods

About ARMOUR Residential REIT, Inc.

ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.

Read more on ARR

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY